Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

Li Peng; Ding HuiGuo; Xu Hui; Zhang ShiBin; Zhang YueNing; Wang ZhenBiao; Wu YanJing; Yu HaiBin

doi:10.3969/j.issn.1001-5256.2017.07.019

Issue 7

Jul. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(7): 1301-1304

PDF( 1568 KB)

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.07.019

Department of Gastroenterology and Hepatology, Beijing You An Hospital, Capital Medical University

Research funding:

Received Date: 2017-01-25
Published Date: 2017-07-20

Abstract

Abstract

Objective To investigate the influence of shortening liver cancer screening interval on the detection of early-stage hepatocellular carcinoma (HCC) in patients with hepatitis B cirrhosis and their prognosis, as well as proper screening schemes for such patients at a high risk of HCC.Methods A total of 310 patients with hepatitis B cirrhosis who were diagnosed and treated in Department of Gastroenterology and Hepatology, Beijing You An Hospital, from January 2007 to January 2008 were enrolled, and according to the screening interval, they were divided into 3-month screening group (group A) with 78 patients and 6-month screening group (group B) with 232 patients.The screening items included serum alpha-fetoprotein and ultrasound and the patients were followed up for 5 years.The patients with HCC screened out were followed up to the endpoint (death or December 31, 2016) .The detection of HCC and prognosis were compared between the two groups.The t-test was used for comparison of continuous data between groups, the chi-square test or Fisher's exact test was used for comparison of categorical data between groups, and the Kaplan-Meier method was used for survival analysis.Results At the end of the5-year follow-up, 73 patients were diagnosed with HCC, with 21 in group A and 52 in group B.Group A had a significantly higher proportion of patients with early-stage HCC (Barcelona Clinic Liver Cancer stage A) than group B [66.7% (14/21) vs 15.4% (8/52) , χ2=18.685, P<0.001].Group A also had a significantly higher proportion of patients who underwent radical surgery than group B (76.2% vs 36.5%, χ2=9.424, P=0.002) .The patients with HCC were followed up to the endpoint, and compared with group B, group A had a significantly longer cumulative survival time (66.4 ± 8.0 months vs 38.1 ± 4.5 months, t=4.295, P=0.038) and a significantly higher cumulative survival rate [71.4% (15/21) vs 46.2% (24/52) , χ2=3.840, P=0.043].Conclusion For patients with hepatitis B cirrhosis, a 3-month screening interval can increase the early detection rate of HCC, bring the opportunity of radical treatment for these patients, and prolong their survival time.
- hepatitis B virus,
- liver cirrhosis,
- carcinoma, hepatocellular,
- early diagnosis,
- prognosis

FullText(HTML)

References(20)

References

[1]QI JH, WANG J, KATAYAMA H, et al.Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma[J].Neoplasma, 2013, 60 (2) :135-142.

[2]VILANA R, FORNER A, GARCIA AN, et al.Hepatocellular carcinoma:diagnosis, staging, and treatment strategy[J].Radiologia, 2010, 52 (5) :385-398.

[3]KUDO M.The 2008 Okuda lecture:management of hepatocellular carcinoma:from surveillance to molecular targeted therapy[J].J Gastroenterol Hepatol, 2010, 25 (3) :439-452.

[4]OMATA M, LESMANA LA, TATEISHI R, et al.Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474.

[5]BRUIX J, SHERMAN M, LLOVET JM, et al.Clinical management of hepatocellular carcinoma.Conclusion of the Barcelona-2000EASL Conference[J].J Hepatol, 2001, 35 (3) :421-430.

[6]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma-an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[7]LI P, CHEN YH, ZHANG SB, et al.Comparison of dierent hepatocarcinoma screening schemes for patients with hepatitis B associated cirrhosis:Detection rate and impact on prognosis[J].World Chin JDig, 2015, 20 (23) :3298-3303. (in Chinese) 李鹏, 陈玉涵, 张世斌, 等.乙型肝炎肝硬化患者不同肝癌筛查方案的比较及对预后影响[J].世界华人消化杂志, 2015, 20 (23) :3298-3303.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.

[9]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部, 原发性肝癌诊疗规则 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[10]FORNER A, REIG ME, de l OPE CR, et al.Current strategy for staging and treatment:the BCLC update and future prospects[J].Semin Liver Dis, 2010, 30 (1) :61-74.

[11]LIN SM, LIN CJ, LIN CC, et al.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less[J].Gut, 2005, 54 (8) :1151-1156.

[12]WANG JH, CHANGCHIEN CS, HU TH, et al.The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients[J].Eur JCancer, 2008, 44 (7) :1000-1006.

[13]TSENG PL, WANG JH, TUNG HD, et al.Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening[J].J Gastroenterol Hepatol, 2010, 25 (8) :1426-1434.

[14]KUO YH, LU SN, CHEN CL, et al.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J].Eur J Cancer, 2010, 46 (4) :744-751.

[15]LLOVET JM, DUCREUX M, LENCIONI R.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.

[16]STEFANIUK P, CIANCIARA J, WIERCINSKA-DRAPALO A.Present and future possibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424.

[17]LIN H, ZHENG WD.The diagnosis and prognostic value of AFP, AFU, TSGF and IL-8 in liver transplantation patients with liver cancer[J].J Clin Exp Med, 2017, 16 (8) :776-780. (in Chinese) 林花, 郑卫东.AFP、AFU、TSGF及IL-8对肝癌患者诊断及肝移植术预后评估的价值研究[J].临床和实验医学杂志, 2017, 16 (8) :776-780.

[18]ZHU QX.Diagnostic value of joint detection of golgin 73, alphafetoprotein, alpha-fetoprotein variants for primary hepatocellular carcinoma[J].China Med Herald, 2016, 13 (5) :130-133. (in Chinese) 诸琴红.高尔基体蛋白73、甲胎蛋白、甲胎蛋白异质体3%联合检测对原发性肝癌的诊断价值[J].中国医药导报, 2016, 13 (5) :130-133.

[19]LI JL, SHAGN J, NING HB, et al.Role of serum abnormal prothrombin protein induced by vitamin K absence or antagonist-II in development and progression of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (1) :171-174. (in Chinese) 李俊利, 尚佳, 宁会彬, 等.PIVKA-II在肝细胞癌诊断及预后判断中的作用[J].临床肝胆病杂志, 2017, 33 (1) :171-174.

[20]KOKUDO N, HASEGAWA K, AKAHANE M, et al.Evidence-based clinical practice guidelines for hepatocellular carcinoma:the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) [J].Hepatol Res, 2015, 45 (2) :123-127.

Relative Articles

[1]	Ying TU, Xue LI, Meijuan CHEN, Huaqian XU, Shanhong TANG. Value of platelet count and related scoring models in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2023.06.009
[2]	Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG. Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(5): 1053-1058. doi: 10.3969/j.issn.1001-5256.2022.05.015
[3]	Xiao YU, Guobing WU, Aibin ZHANG, Xiaolong CHENG, Min LIU, Zenan HU, Ya ZHENG, Yuping WANG, Zhaofeng CHEN. Role of platelets in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1426-1430. doi: 10.3969/j.issn.1001-5256.2022.06.043
[4]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[5]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of FibroScan combined with gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis in patients with chronic hepatitis B:A preliminary study[J]. Journal of Clinical Hepatology, 2019, 35(2): 334-337. doi: 10.3969/j.issn.1001-5256.2019.02.018
[6]	Huang ChunMing, Yang Zhan, Nie YuQiang, Hu ZhongWei, Zhou YongJian, Zhan YuanJing, Guo JiaWei, Yu WeiHua. Value of gamma-glutamyl transpeptidase-to-platelet ratio in predicting liver fibrosis stage in chronic hepatitis B patients in Guangdong, China[J]. Journal of Clinical Hepatology, 2018, 34(6): 1204-1208. doi: 10.3969/j.issn.1001-5256.2018.06.015
[7]	Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
[8]	Lin Yan, Li Xun. Research advances in the role of platelets in liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(11): 2243-2246. doi: 10.3969/j.issn.1001-5256.2017.11.043
[9]	Chen Nian, Huang WeiE, Su MingHua, Jiang JianNing. Correlation between platelet indices and liver pathological staging: an analysis of 167 patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(1): 106-109. doi: 10.3969/j.issn.1001-5256.2016.01.019
[10]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[11]	Zheng JunFu, Cai ZhaoHua, Zhang Xin, Lou JinLi, Zhao WenMin, Li Peng, Li Bing, Li Lei, Dong PeiLing, Ding HuiGuo. Value of single or combined measurement of serum PCT,peripheral WBC,and WBC/PCT for early diagnosis of bacterial infection in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 209-213. doi: 10.3969/j.issn.1001-5256.2015.02.016
[12]	Gao Chun, Fang Long, Yao ShuKun. Correlation of GGT with AFP and diagnostic value of GGT for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 921-925. doi: 10.3969/j.issn.1001-5256.2014.09.021
[13]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022
[14]	Ding ShengNan, Yang WeiMin, Niu JunQi. Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(6): 556-559. doi: 10.3969/j.issn.1001-5256.2014.06.020
[15]	Jin GuoHua, Po YunFeng, Chen ZhaoJie. Comparison on hematoblastic relevant parameter from patients with liver cirrhosis after heptitis B and patients with alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(2): 102-104.

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	张玉婷，施欢，李虤，沈波. FibroTouch联合GGT/PLT比值对诊断乙型肝炎肝纤维化的临床价值. 江西医药. 2022(02): 206-209+216 .
2.	杜乔慧，吴克俭，王争争. GP73、GPR对慢性乙型肝炎患者肝硬化的诊断价值. 胃肠病学和肝病学杂志. 2022(07): 758-763 .
3.	鲁荣华. 血清IL-2和IL-10对重度慢性乙型肝炎患者糖皮质激素治疗预后的评估价值. 中国卫生工程学. 2020(01): 83-85 .
4.	毛桂芸，张永飞，郭延生，陶金忠. 山楂对围产期奶牛肝功能和血脂的影响. 中国奶牛. 2020(08): 36-39 .
5.	陈晓玲，宋倩. 剪切波弹性成像和γ-谷氨酰转肽酶/血小板比用于诊断慢性乙型肝炎患者肝纤维化. 中国医学影像技术. 2020(10): 1499-1503 .
6.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. FibroScan联合GGT/PLT比值预测慢性乙型肝炎患者肝纤维化的初步探讨. 临床肝胆病杂志. 2019(02): 334-337 . 本站查看
7.	张小磊. 血清ALT、AST、GGT、HBV-DNA联合检测在慢性乙型肝炎病情评估中的应用. 内蒙古医学杂志. 2019(02): 211-212 .
8.	尹国云. 瞬时弹性超声检测对蒙古族地区慢性乙型病毒性肝炎患者抗病毒治疗临床指导意义的研究. 世界复合医学. 2019(06): 90-92+114 .
9.	黄春明，胡中伟，聂玉强，周永健，詹远京，郭家伟，余卫华. 无创诊断模式预测慢性乙型肝炎合并非酒精性脂肪肝患者肝纤维化的价值. 胃肠病学和肝病学杂志. 2019(08): 915-918 .
10.	黄春明，杨湛，聂玉强，胡中伟，周永健，詹远京，郭家伟，余卫华. GGT/PLT比值对广东地区慢性乙型肝炎患者肝纤维化分期的预测价值. 临床肝胆病杂志. 2018(06): 1204-1208 . 本站查看
11.	李曼，李涛，刘振杰，曹永坚，钟伟国，余婷玉，何敏，徐宁. 以血清学指标比值为变量的肝纤维化诊断模型构建与评价. 山东医药. 2018(18): 17-20 .
12.	李曼，张军，李涛，罗强，钟伟国，李嘉胜，徐宁. ADA/PLT、ALP/PLT比值对肝纤维化的诊断价值. 中国实验诊断学. 2017(11): 1923-1926 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2531) PDF downloads(425)

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2017.07.019